Core Insights - Inspira Technologies has received approval from Israel's largest healthcare provider to validate its INSPIRA ART100 system for organ transplant procedures, marking a significant advancement in its clinical applications [1][2][4] - The INSPIRA ART100 system is designed to maintain organ viability through advanced blood oxygenation, providing out-of-body blood oxygenation during transplant procedures and recovery [2][3] - The clinical validation will generate valuable data to support the development of the INSPIRA ART500 system, which aims to revolutionize respiratory care by enabling direct blood oxygenation without mechanical ventilation [3][4] Company Overview - Inspira Technologies specializes in innovative respiratory support and diagnostic technologies, with its flagship product, the INSPIRA ART500 system, currently under development [5] - The INSPIRA ART100 system has received FDA 510(k) clearance for cardiopulmonary bypass procedures and Israeli AMAR certification for both cardiopulmonary bypass and ECMO procedures [4][5] - The company is also developing the HYLA blood sensor technology for continuous, real-time blood monitoring without blood draws, along with other pipeline products [5]